[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heel-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heel-pain":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100638228","barefoot-walking-vs-standardised-conservative-care-for-plantar-fasciopathy-100638228",false,"NCT07600229","Barefoot Walking VS Standardised Conservative Care for Plantar Fasciopathy","Clinical and Economic Effectiveness of Barefoot Walking Compared to Standardised Conservative Care for the Treatment of Plantar Fasciopathy: a Pragmatic Randomised Controlled Trial","Inclusion Criteria:\n\n* Aged 18-70 years;\n* Clinical diagnosis of Plantar Fasciopahty, defined by: a) Pain localised to the medial calcaneal tubercle of sharp or stabbing quality; b) Pain worst with the first few steps in the morning or after a period of rest (first-step pain); c) Pain reproduced with palpation of the medial calcaneal tubercle OR positive Windlass Test;\n* Symptom duration greater than 4 weeks;\n* Able to walk independently without a mobility aid\n* Able to provide informed consent and comply with study protocol\n\nExclusion Criteria:\n\n* Prior surgery on the affected foot\n* Diabetes with peripheral neuropathy or other neurological condition affecting lower limb sensation or motor control\n* Active inflammatory arthropathy, uncontrolled vascular disease, or inability to walk unaided\n* Current or recent (less than 6 months) bony stress fracture or other acute foot or ankle injury on the affected side\n* Pregnancy during the intervention period\n* BMI greater than 40 kg\u002Fm²\n* Corticosteroid injection to the affected foot within the previous 3 months\n* Night splints initiated less than 4 weeks prior to enrolment\n* Any condition that would make participation unsafe, including open foot wounds","ALL","18 Years","70 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a barefoot walking programme can treat plantar fasciopathy (heel pain) in adults aged 18-70. The main questions it aims to answer are:\n\n* Does a barefoot walking programme reduce heel pain compared to a standardised stretching and strengthening programme?\n* Does a barefoot walking programme improve foot function and quality of life in adults with plantar fasciopathy?\n\nResearchers will compare a barefoot walking programme to a standardised stretching and strengthening programme to see if barefoot walking is an effective conservative management approach for plantar fasciopathy.\n\nParticipants will:\n\n* Be randomly assigned to either a barefoot walking programme or a stretching and strengthening programme\n* Complete a 12-week home-based exercise programme\n* Complete short weekly questionnaires throughout the 12 weeks\n* Complete 3 follow-up surveys over 6 months after the intervention ends\n* Receive education on load management and plantar fasciopathy",[27,28,29,30],"Plantar Fasciopathy","Plantar Fasciitis","Plantar Fasciitis, Chronic","Heel Pain",[32,33,34,35,36,37,38],"Plantar fasciopathy","Plantar fasciitis","Heel pain","Barefoot walking","Foot pain","Musculoskeletal","Physical therapy","RECRUITING","2026-05-20",{"date":42,"type":43},"2026-05-22","ACTUAL",{"date":45,"type":43},"2026-05-07",{"date":47,"type":21},"2027-10-31",{"name":49,"class":50},"Elisabetta Brigo","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100611538","sakurabead-used-as-resorbable-embolic-for-plantar-fascia-embolization-100611538","NCT07241884","SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization","SURE-PF","Inclusion Criteria:\n\n1. Patient is able and willing to provide written informed consent, and\n2. Age 18 to 75 years (inclusive), and\n3. Clinical diagnosis of PF with proximal plantar fascia thickness greater than 4mm and areas of hypoechogenicity.\n\nExclusion Criteria:\n\n1. Acute internal derangement of the foot including acute meniscal, ligament or bone injury, or\n2. Sensory or motor neuropathy of the feet, or\n3. Heel pain caused by stress fractures, nerve entrapment, or inflammatory conditions such as arthritis, gout, or bursitis, or\n4. Prior surgical repair or plantar fascia rupture in the involved foot, or\n5. Local infection in either foot, or\n6. Contraindication to MRI, or\n7. Active pregnancy as demonstrated by urine or serum β-hCG or lactating female\n8. Unable to provide informed consent or comply with the conditions of the study, or\n9. At the discretion of the Principal Investigator","75 Years",{"count":61,"type":21},45,[24],"This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from pain secondary to plantar fasciitis.",[65,30,66],"Plantar Fascitis","Musculoskeletal Diseases",[68,69,70,30],"Fasciitis","Musculoskeletal disease","Foot disease","2025-11-17",{"date":73,"type":43},"2025-11-21",{"date":75,"type":43},"2025-10-20",{"date":77,"type":21},"2027-03",{"name":79,"class":80},"CrannMed","INDUSTRY"]